EP300 and acute lymphoblastic leukemia: In comparison to B-ALL with other genomic lesions, EP300-ZNF384-positive B-ALL is characterized by a distinct gene expression signature predominantly enriched in the upregulation of Janus kinase/signal transducers and activators of transcription (JAK/STAT) and cell adhesion pathways, and downregulation of the cell cycle and DNA repair pathways [7, 8].